Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Solid Tumors 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 9Paclitaxel 8Carboplatin 7atezolizumab 6Sunitinib 5navitoclax 4Topotecan 4Irinotecan 4Docetaxel 4Bevacizumab 4pazopanib 3liposomal doxorubicin 3cobimetinib 3Nivolumab 3Erlotinib Hydrochloride 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2temsirolimus 2selicrelumab 2plocabulin 2envafolimab 2darinaparsin 2brigimadlin 2adavosertib 2Tablets 2Sorafenib 2Rifampin 2RG7388 2Panitumumab 2NVP-BKM120 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumors × CB-839 × Clear all
NCT03965845 2022-09-19

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Calithera Biosciences, Inc

Phase 1/2 Completed
53 enrolled
Other solid neoplasmThoracic

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡